Ottawa: Remdesivir saved many lives during the deadly second wave of COVID-19. Now, a new study reveals that remdesivir has reduced the need for ventilators in inpatients compared to standard treatment for COVID-19.
A study entitled “Canadian Treatment of COVID-19 (CATCO)” was published in Canada’s leading medical journal, the Canadian Medical Association Journal.
This study was a sub-study of the World Health Organization-related band study to examine the effects of various treatments for COVID-19, funded by the Canadian Institute of Health. In a CATCO study involving 52 Canadian hospitals, Canadian researchers studied the effects of remdesivir on COVID-19 inpatients from August 14, 2020 to April 1, 2021.
Of 1282 patients, about half were randomized to receive treatment with remdesivir and the rest were assigned to controls receiving standard of care. There was mixed evidence of the effects of the reused antiviral drug remdesivir on people with COVID-19.
In a Canadian study led by researchers at the University of British Columbia and the Sunnybrook Health Science Center, 8% of patients who were not ventilated at the start of the study were ventilated in 8% of patients who were on ventilator. It turns out that there is a need for a vessel. 15% of patients receiving standard of care. In addition, patients treated with remdesivir were able to remove oxygen and ventilator faster than those receiving standard treatment.
Dr. Srinivas Murthy of the University of British Columbia, along with co-authors, “The benefits of treatment are most obvious to prevent the need for mechanical ventilation and add value to less severe patients to avoid progression during hospitalization. It suggests that it is likely to bring. “
“This can have significant impacts on patients and the medical system, especially if the ICU capacity, ventilator, or oxygen supply is limited,” he added.
The CATCO trial was able to collect more detailed data than in other countries and target patients of different ethnicities. This was especially important for applications in multicultural societies where other countries and people live. The largest single-country study of remdesivir reported so far.
These results have been added to a larger global study of how remdesivir can be used in other countries.
“CATCO’s findings help address the issue of generalizability of large, simple protocols in various hospitals and healthcare systems in low-income, middle-income, and high-income countries. It also complements solidarity. ”The authors concluded.
https://www.siasat.com/remdesivir-for-covid-19-found-to-reduce-need-for-mechanical-ventilation-study-2263680/ COVID-19 remdesivir was found to reduce the need for mechanical ventilation: study